Discovery of <i>N</i>-Aryl-<i>N</i>′-[4-(aryloxy)cyclohexyl]squaramide-Based Inhibitors of LXR/SREBP-1c Signaling Pathway Ameliorating Steatotic Liver Disease: Navigating the Role of SIRT6 Activation-Reference-Cited by-同舟云学术

Discovery of N-Aryl-N′-[4-(aryloxy)cyclohexyl]squaramide-Based Inhibitors of LXR/SREBP-1c Signaling Pathway Ameliorating Steatotic Liver Disease: Navigating the Role of SIRT6 Activation

Published:2024-09-11 Issue: Volume: Page:
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Nguyen Long Huu¹,Cho Ye Eun¹,Kim Soyeong¹²,Kim Yeonsoo¹,Kwak Jinsook¹,Suh Jung-Soo³,Lee Jinyoung¹,Son Kyuwon¹,Kim Minseong¹,Jang Eun Seo¹,Song Naghyun¹,Choi BuChul¹,Kim Jiah¹,Tak Yealin¹,Hwang Taeyeon⁴,Jo Jeyun¹,Lee Eun-Woo⁵,Kim Sang-Bum²,Kim Sanghyun⁶,Kwon Oh-Bin²^ORCID,Kim Sangok⁴,Lee Seoung Rak¹⁷,Lee Haeseung¹⁷,Kim Tae-Jin³^ORCID,Hwang Seonghwan¹⁷,Yun Hwayoung¹⁷^ORCID

Affiliation:

1. College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea

2. New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, Republic of Korea

3. Department of Integrated Biological Science, Pusan National University, Busan 46241, Republic of Korea

4. Korea Bioinformation Center, Korea Research Institute of Bioscience & Biotechnology, Daejeon 34141, Republic of Korea

5. Metabolic Regulation Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, Republic of Korea

6. Laboratory Animal Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, Republic of Korea

7. Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of Korea

Funder

Korea Research Institute of Bioscience and Biotechnology

National Research Foundation of Korea

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.4c01597

Reference59 articles.

1. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease

2. Hepatic lipid droplets: A balancing act between energy storage and metabolic dysfunction in NAFLD

3. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications

4. Increased risk of cardiovascular disease and chronic kidney disease in NAFLD

5. Global Prevalence and Clinical Characteristics of Metabolic-associated Fatty Liver Disease: A Meta-Analysis and Systematic Review of 10 739 607 Individuals